Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-Dose Rituximab, Cyclophosphamide, and Corticosteroids in Primary Membranous Nephropathy
NCT05679336Phase 2Recruiting
- Sponsor
- First Saint Petersburg State Medical University
- Start
- May 2018
- Primary completion
- Aug 2024
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of rituximab, cyclophosphamide in primary membranous nephropathy (PMN), sponsored by First Saint Petersburg State Medical University. Started May 2018; status: recruiting.
02
Drugs
rituximabcyclophosphamide
03
Conditions
primary membranous nephropathy (PMN)
Beyond the preview
Go deeper on NCT05679336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05679336.